Abstract
PURPOSE: Epstein-Barr virus (EBV) reactivation in allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients can lead to significant complications including post-transplant lymphoproliferative disease. Despite progress in managing EBV reactivation in allo-HCT recipients, data on clinical characteristics and prognostic implications of EBV viral load remain limited. Here, we aim to evaluate the prevalence, identify risk factors, and assess the clinical implications of EBV-DNA positivity in allo-HCT recipients. METHODS: A retrospective audit of laboratory records for EBV load monitoring in allo-HCT recipients during the period from 2021 to 2023 was performed. EBV viral load was assessed using quantitative PCR. The medical records were reviewed for clinical features, identifying risk factors, and prognostic impact of EBV-DNA positivity. RESULTS: A total of 40 patients with a median age of 20.5 years were included. Patients were divided into two groups based on presence (>600 copies/mL) and absence of EBV-DNA. We observed EBV-DNA positivity in 16 (40%) patients with a median EBV viral load of 12,400 copies/ml. Patients with EBV-DNA positivity exhibited a higher incidence of acute graft versus host disease (p=0.039). Patients with EBV-DNA positivity tended to have poorer 1-year overall survival and disease-free survival, although the results did not reach statistical significance. CONCLUSION: Our data highlights the importance of monitoring EBV viral load in predicting the outcome in terms of overall survival in allo-HCT recipients. The development of GVHD has also surfaced as a significant element increasing the likelihood of EBV-DNA positivity. It is imperative to conduct further research and establish comprehensive protocols for the routine monitoring and management of EBV post-allo-HCT.